CCM
BSX icon

CrestPoint Capital Management’s Boston Scientific BSX Stock Holding History

CrestPoint Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-46,500
Closed -$616K – 221
2014
Q4 		$616K Hold
46,500
– – 0.33% 107
2014
Q3 		$549K Buy
46,500
+5,500
+13% +$69.3K 0.33% 110
2014
Q2 		$524K Buy
+41,000
New +$533K 0.31% 115

Other funds holding BSX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return

CrestPoint Capital Management's BSX Position: Q1 2015 in Review

CrestPoint Capital Management sold out of Boston Scientific (BSX) in Q1 2015, closing a stake of 46,500 shares — an estimated $616K sold.

CrestPoint Capital Management first reported a position in BSX in Q2 2014 and held it in 3 quarters. The position peaked at $616K in Q4 2014. 471 funds tracked by Wall St. Rank hold BSX as of Q1 2015.

  • CrestPoint Capital Management reported no remaining Boston Scientific position as of Q1 2015 after selling out during the quarter.
  • CrestPoint Capital Management sold 46,500 Boston Scientific shares in Q1 2015, an estimated $616K.
  • CrestPoint Capital Management first reported a position in Boston Scientific in Q2 2014 and held it in 3 quarters.
  • CrestPoint Capital Management's Boston Scientific position peaked at $616K in Q4 2014.
  • 471 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2015.

Based on CrestPoint Capital Management's 13F filing for Q1 2015, filed 14 Apr 2015.